SRPTSarepta Therapeutics, Inc.同业对比
Sarepta Therapeutics, Inc. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRPT本股 | $2.1B#9 | — | 1.4x#3 | 1.1x#3 | 4.3%#8 | -403.3%#14 | -37.5%#5 | -46.7%#9 | -73.0%#4 | — | 6.9%#9 | — |
| SLS | $2.3B#1 | — | 16.5x#13 | — | -100.0%#12 | 13.0%#5 | — | -19.5%#6 | — | — | 600.6%#1 | — |
| OCUL | $2.2B#2 | — | 4.3x#5 | 42.8x#9 | -18.5%#11 | -37.4%#9 | -519.8%#9 | -51.1%#10 | — | — | -20.4%#13 | — |
| PVLA | $2.2B#3 | — | 10.0x#12 | 50.8x#10 | 65.3%#4 | -139.3%#11 | -90.2%#7 | -19.2%#5 | — | — | 155.8%#2 | — |
| PBH | $2.2B#5 | 12.8x#1 | 1.1x#2 | 2.0x#4 | -4.3%#10 | -11.3%#8 | 28.4%#1 | 9.9%#1 | 5.9%#1 | 4#1 | -28.7%#14 | — |
| GENB | $2.2B#4 | — | 4.8x#7 | — | — | — | — | 0.0%#2 | — | — | — | — |
| BHC | $2.1B#7 | — | — | 0.2x#1 | 6.7%#7 | 441.3%#1 | 17.7%#2 | — | 3.6%#2 | — | -3.5%#10 | 16.7%#1 |
| TRVI | $2.1B#6 | — | 6.6x#9 | — | — | 10.7%#7 | — | -13.3%#4 | — | — | 75.1%#4 | — |
| BHVN | $2.1B#8 | — | 171.4x#15 | — | — | 12.7%#6 | — | -6045.0%#15 | — | — | -10.6%#11 | — |
| NUVB | $2.1B#10 | — | 8.2x#10 | 32.9x#7 | 699.0%#1 | 64.0%#3 | -338.7%#8 | -80.6%#12 | -87.4%#5 | — | 86.8%#3 | — |
| ZBIO | $2.0B#11 | — | 8.3x#11 | 204.6x#11 | 100.0%#3 | -140.6%#12 | -3830.6%#11 | -152.9%#14 | -296.6%#6 | — | 60.9%#6 | — |
| AGIO | $2.0B#12 | — | 1.9x#4 | 36.6x#8 | 48.0%#5 | -161.3%#13 | -873.9%#10 | -40.3%#8 | — | — | -12.8%#12 | — |
| RAPP | $2.0B#13 | — | 4.6x#6 | — | — | -42.4%#10 | — | -26.4%#7 | — | — | 49.2%#7 | — |
| ZYME | $1.9B#14 | — | 23.7x#14 | 18.0x#6 | 38.9%#6 | 33.9%#4 | -87.3%#6 | -100.9%#13 | — | — | 62.9%#5 | — |
| PRGO | $1.9B#15 | — | 0.7x#1 | 0.4x#2 | -2.8%#9 | -729.7%#15 | -26.4%#4 | -56.7%#11 | -20.9%#3 | 4#1 | -32.0%#15 | 8.6%#2 |
| STOK | $1.8B#16 | — | 5.3x#8 | 9.9x#5 | 404.5%#2 | 92.3%#2 | -11.2%#3 | -2.0%#3 | — | — | 20.9%#8 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议